March 4, 2013
- The global event for biotech to take place in Chicago, IL April 22-25, 2013 -
WASHINGTON - The 2013 BIO International Convention will feature six diverse Super Sessions highlighting pressing industry topics such as the state of the industry, emerging R&D initiatives between public and private sectors, the future of biotechnology under the Affordable Care Act (ACA) and the future of deal-making and global innovation. Hosted by the Biotechnology Industry Organization (BIO), the Convention, celebrating its 20(th) anniversary, will take place April 22-25, 2013 at McCormick Place in Chicago, Ill.
"Attendees have come to expect a dynamic group of C-level speakers from major biotechnology and pharmaceutical companies to be featured during our Super Sessions," said BIO President & CEO Jim Greenwood. "This year's line-up will not disappoint as it promises to offer insight and valuable advice on the current economic development, key policy issues and major trends that will impact the future of the global industry."
Super Sessions include:
The Return of the Pipeline Deal
Since 2007 we have seen a decline in the pipeline deals across biotech. It used to be common to read about the next billion dollar biobuck deal that your neighborhood small biotech struck with pharma. But how often do we read those headlines these days? Post megamerger, post-patent cliff, and post-financial crises, the reality is that large pharma and big biotech have been much harder to entice for small start-ups. This panel will hear from industry leaders behind the next big deals as they discuss the future of deal-making.
In advance of this interactive panel discussion, Campbell Alliance and BIO will present updated findings from two unique forward-looking measures of deal-making in the industry -- the Campbell Alliance Dealmakers' Intentions Survey and the BIO One-on-One Partnering Forecast.
Wednesday, April 24, 2013, 2:00 p.m. -- 3:30 p.m.
Moderated by Jeff Stewart, Director, Campbell Alliance and David Thomas, Director, Research & Industry Analysis, Biotechnology Industry Organization
Speakers: Bahija Jallal, PhD, Executive Vice President, Research & Development, MedImmune, Roger Pomerantz, MD, F.A.C.P., World Wide Head of Licensing & Acquisitions and Knowledge Management, Senior Vice President, Merck Research Laboratories
The BIO International Convention also features the industry's largest partnering event, hosting a record breaking 25,000+ partnering meetings in 2012. More than 4,000 companies participated in One-on-One Partnering meetings in the BIO Business Forum(TM) and in the BIO Exhibition. These efficient meetings foster the opportunity for companies to initiate business contacts in a friendly environment and schedule meetings prior to the Convention.
Advance media registration is now available for qualified reporters working full time for print, broadcast and web publications with valid press credentials. To register, please visit here.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling "innovations transforming our world."